OCLN and Chronic colitis: QHCY can significantly alleviate clinical symptoms of DSS-induced chronic colitis in mice, protect the function of intestinal mucosal barrier, and improve intestinal microflora by i) inhibiting the expression of TNF-α, IL-6, and IL-1β inflammatory mediators, ii) maintaining the expression of tight junction protein occludin, ZO-1, and MUC2, and iii) improving the diversity of intestinal microflora and regulating the structure and composition of intestinal microflora in mice with chronic colitis.